within Pharmacolibrary.Drugs.ATC.J;

model J07AM52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>A combination product containing tetanus toxoid, a vaccine used to induce active immunity against tetanus, together with tetanus immunoglobulin, which provides passive immediate immunity to tetanus. It is typically used for post-exposure prophylaxis in individuals with risk of tetanus infection, especially when immunization status is uncertain or incomplete. Both components are approved and widely used for prevention of tetanus.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults; no direct pharmacokinetic studies or publications were found for the combination product.</p><h4>References</h4><ol><li><p>Gupta, PN, et al., &amp; Vyas, SP (2005). Tetanus toxoid-loaded transfersomes for topical immunization. <i>The Journal of pharmacy and pharmacology</i> 57(3) 295â€“301. DOI:<a href=&quot;https://doi.org/10.1211/0022357055515&quot;>10.1211/0022357055515</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15807984/&quot;>https://pubmed.ncbi.nlm.nih.gov/15807984</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J07AM52;
